Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Tacrine
Lancet 345:625-630, Davis,K.L.&Powchik,P., 1995
Serotonin Syndrome
Neurol 45:219-223, Bodner,R.A.,et al, 1995
Vitamin C and Risk of Death from Stroke and Coronary Heart Disease in Cohort of Elderly People
BMJ 310:1563-1566, 15481995., Gale,G.R.,et al, 1995
The Narcolpetic Syndrome
JNNP 59:221-224, Parkes,J.D.,et al, 1995
The Use of Sumatriptan in Patients with Monoamine Oxidase Inhibitors
Neurol 45:1039-1040, Diamond,S., 1995
Parkinsonism Unmasked by Lovastatin
Ann Neurol 37:685-686, Muller,T.,et al, 1995
Spinocerebellar Ataxias and Ataxins
NEJM 333:1351-1353, Rosenberg,R.N., 1995
Primary Prevention of Stroke
NEJM 333:1392-1400, Bronner,L.L.,et al, 1995
Systemic Sclerosis Sine Scleroderma:An Unusual Presentation in Scleroderma Renal Crisis
J Rheumatol 22:557-560, Molina,J.F.,et al, 1995
Adult-Onset Spinocerebellar Dysfunction Caused by a Mutation in the Gene for the a-Tocopherol-Transfer Protein
NEJM 333:1313-1318, 13511995., Gotoda,T.,et al, 1995
The Impact of New Pharmaceutical Agents on the Cost of Neurologic Care
Neurol 45:569-572, Gunderson,C.H., 1995
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Comparative Study of Selegiline Plus L-Dopa-Carbidopa VS L-Dopa-Carbidopa Alone in Trtm of Parkinson's Disease
Ann Neurol 37:95-98, Brannan,T.&Yahr,M.D., 1995
Peripheral Neuropathy with Bezafibrate
BMJ 309:929, Ellis,C.J.,et al, 1994
Hepatotoxic Effects of Tacrine Administration in Patients with Alzheimer's Disease
JAMA 271:992-998, Watkins,P.B.,et al, 1994
30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients with Alzheimer's Disease
JAMA 271:985-991, 10231994., Knapp,M.J.,et al, 1994
Efficacy of Tacrine and Lecthin in Mild to Moderate Alzheimer's Disease:Double Blind Trial
BMJ 308:879-883, Maltby,N.,et al, 1994
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Selegiline in the Treatment of Narcolepsy
Neurol 44:2095-2101, Hublin,C.,et al, 1994
HMG-CoA Reductase Inhibitor Therapy and Peripheral Neuropathy
Ann Int Med 120:970, Jacobs,M.B., 1994
Pharmacogenetics and Drug Metabolism of Newer Antidepressant Agents
J Clin Psychiatry 55:38-45, DeVane,C.L., 1994
When Selegiline is Prescribed, Stelazine May be Mistakenly Dispensed
Neurol 43:228, Zweig,R.M.&Davis,P.H., 1993
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993
Tolrestat for Mild Diabetic Neuropathy, A 52-Week Randomized, Placebo-Controlled Trial
Ann Int Med 118:7-11, Guigliano,D.,et al, 1993
Comparisons of Therapeutic Effects of Levodopa
Levodopa & Selegiline, & Bromocriptine in Pts with Early, Mild Parkinson's, Parkinson's Res Grp in U, , BMJ 372,1993., 1993
The Sorbinil Retinopathy Trial:Neuropathy Results
Sorbinil Retinopathy Trial Research Group, Neurol 43:1141-11491993., , 1993
Acetazolamide-Induced Nephrolithiasis:Implications for Treatment of Neuromuscular Disorders
Neurol 43:1105-1106, Tawil,R.,et al, 1993
One-Year Reduction and Longitudinal Analysis of Carotid Intima-Media Thickness Associated with Colestipol/Niacin Therapy
Stroke 24:1779-1783, Mack,W.J.,et al, 1993
The Neurologic Syndrome of Vitamin E Deficiency:A Significant Cause of Ataxia
Neurol 43:2167-2169, Kayden,H.J., 1993
The Antiparkinson Efficacy of Deprenyl Derives from Transient Improvement that is Likely to be Symptomatic
Ann Neurol 32:795-798, Schulzer,M.,et al, 1992
Idiopathic Intracranial Hypertension:Report of Seven Cases
Am J Med 93:391-395, Jain,N.&Rosner,F., 1992
Selegiline as Initial Treatment of De Novo Parkinsonian Patients
Neurol 42:339-343, Myllyla,V.V.,et al, 1992
Deprenyl Effects of Levodopa Pharmacodynamics, Mood, and Free Radical Scavenging
Neurol 42:541-544, Baronti,F.,et al, 1992
Antibodies to Oxidised LDL in Atherosclerosis
Editorial, Lancet 339:899-9001992., , 1992
Serum Concentrations of Vitamins A and E and Early Outcome after Ischaemic Stroke
Lancet 339:1562-1565, DeKeyser,J.,et al, 1992
The Effect of Acetazolamide on Essential Tremor:An Open-Label Trial
Neurol 42:1394-1395, Busenbark,K.,et al, 1992
Treatment of Nocturnal Leg Cramps, A Crossover Trial of Quinine vs Vitamin E
Arch Int Med 152:1877-1880, Connolly,P.S.,et al, 1992
Nerve Agents:A Review
Neurol 42:946-950, Gunderson,C.H.,et al, 1992
A Controlled Trial of Tacrine in Alzheimer's Disease
JAMA 268:2523-2529, 25641992., Farlow,M.,et al, 1992
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Dissease
NEJM 327:1253-1259, 13061992., Davis,K.L.,et al, 1992
Acetazolamide-Responsive Vestibulocerebellar Syndrome:Clinical & Oculographic Features
Neurol 41:429-433, Baloh,R.W.&Winder,A., 1991
Tacrine in Alzheimer's Disease
Lancet 337:989-992, Eagger,S.A.,et al, 1991
Severe Adverse Interaction Between Pethidine and Selegiline
Lancet 337:246, Zornberg,G.L.,et al, 1991
Gemfibrozil-Induced Myopathy
Arch Int Med 151:1873-1874, Magarian,G.J.,et al, 1991
Cholesterol-Lowering Agent Myopathy (CLAM)
Neurol 41:1159-1160, London,S.F.,et al, 1991
Pyridostigmine Used as a Nerve Agent Pretreatment Under Wartime Conditions
JAMA 266:693-695, Keeler,J.R.,et al, 1991
DATATOP and Clinical Neuromythology IX
Special Correspondence, Neurol 41:771-7771991., , 1991